Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.97 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.97 |
| ▸ | NPC1 | O15118 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertraline SCHEMBL5741903 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL29406979 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL29895228 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL23230 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL3866334 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL7327367 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL4963372 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL1560715 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL33371 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT | |
| Sertraline SCHEMBL4620487 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087661-A1 | Treatment of CNS disorders with trans 4-3(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine | SEPRACOR, INC. | 2004-05-06 | — | — | US | disclosed |
| WO-2001049638-A2 | A PROCESS FOR CONVERTING STEREOISOMERS OF SERTRALINE INTO SERTRALINE | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2001-07-12 | — | — | WO | disclosed |
| EP-0595851-B1 | PROCESS FOR PREPARING SERTRALINE INTERMEDIATES | PFIZER LTD (GB) | 1996-01-10 | — | — | EP | disclosed |
| US-5442116-A | Process for preparing sertraline intermediates | PFIZER INC. (US) | 1995-08-15 | — | — | US | disclosed |
| WO-1993001161-A1 | PROCESS FOR PREPARING SERTRALINE INTERMEDIATES | PFIZER LIMITED (GB) | 1993-01-21 | — | — | WO | disclosed |
| US-4556676-A | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0028901-B1 | ANTIDEPRESSANT DERIVATIVES OF TRANS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-03-02 | — | — | EP | disclosed |
| EP-0028901-A1 | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087661-A1 | Treatment of CNS disorders with trans 4-3(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine | PNMT, HNMT, TPMT | SLC6A4 7/4885MEN1 207/4885KMT2A 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.